BioCentury | Feb 22, 2020
Product Development

FDA approves Lundbeck's Vyepti, the first CGRP inhibitor for migraine delivered IV

...from established subcutaneous drugs in its class. Already on the market are CGRP inhibitors Ajovy fremanezumab-vfrm...
BioCentury | Sep 24, 2019
Company News

Lundbeck, Alder negotiated ex-U.S. deal before opting for takeout

...market in its class, following migraine prevention drugs Aimovig erenumab-aooe from Amgen Inc. (NASDAQ:AMGN); Ajovy fremanezumab-vfrm...
BioCentury | Sep 16, 2019
Company News

Lundbeck enters migraine race with $2B takeout of Alder

...are already on the market to prevent migraine: Aimovig erenumab-aooe from Amgen Inc. (NASDAQ:AMGN); Ajovy fremanezumab-vfrm...
BioCentury | Aug 8, 2019
Company News

Aug. 7 Company Quick Takes: Panel backs narrower PrEP label for Descovy; plus Teva, Blueprint, DBV and more

...NYSE:TEVA; Tel Aviv:TEVA) reported slightly higher quarterly sales of its recently launched migraine drug Ajovy fremanezumab-vfrm...
BioCentury | Jul 31, 2019
Company News

Amgen still head of class in CGRP-migraine

...Aviv:TEVA) is expected to report 2Q19 revenues for the third approved mAb against CGRP, Ajovy fremanezumab-vfrm...
...September. Consensus figures provided by FactSet. Mary Romeo, Assistant Editor Aimovig, erenumab-aooe (AMG 334) Ajovy, fremanezumab-vfrm (TEV-48125, lbr-101, rn-307) Emgality...
BioCentury | Apr 24, 2019
Financial News

Why Satsuma investors see room for another migraine therapy

...Inhibitor" ). Approved anti-CGRP mAbs include Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY), Ajovy fremanezumab-vfrm...
BioCentury | Apr 22, 2019
Company News

FDA accepts BLA for Alder's migraine therapy for infusion

...is the only delivered via infusion. Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY), Ajovy fremanezumab-vfrm...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...FDA has approved three anti-CGRP therapies -- Emgality galcanezumab-gnlm from Eli Lilly and Co., Ajovy fremanezumab-vfrm...
BioCentury | Mar 18, 2019
Company News

Biohaven spends $105M for faster review of oral CGRP inhibitor

...indication. The approved anti-CGRP drugs are Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY), Ajovy fremanezumab-vfrm...
BioCentury | Mar 1, 2019
Clinical News

Alder submits BLA for migraine therapy, raises $130M in follow-on

...is the only delivered via infusion. Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY), Ajovy fremanezumab-vfrm...
Items per page:
1 - 10 of 85